ArticleTranslational cancer research2025
Prognostic implications of store-operated calcium entry signatures and immune dynamics in neuroblastoma via machine learning.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).CPT: pharmacometrics & systems pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroblastoma is a highly heterogeneous pediatric malignancy, with high-risk cases exhibiting poor clinical outcomes. Store-operated calcium entry (SOCE) channels have been implicated in cancer progression, yet their prognostic significance in neuroblastoma remains unclear. This study aimed to investigate the relevance of SOCE-related genes in predicting patient prognosis and guiding therapeutic strategies. Methods: We performed unsupervised clustering based on SOCE-related gene expression in multiple neuroblastoma RNA sequencing (RNA-seq) datasets. A prognostic scoring system, the SOCE_Score, was developed using machine learning algorithms. The model's predictive performance was validated across independent datasets. Immune characteristics were assessed using established deconvolution algorithms, and candidate therapeutic compounds were identified via the Connectivity Map (CMap) platform. Results: Two distinct molecular clusters were identified, differing significantly in survival outcomes, immune infiltration, and stemness signatures. The SOCE_Score stratified patients with high accuracy and outperformed conventional clinical predictors. Lower SOCE_Score groups were associated with favorable immune landscapes and greater responsiveness to immune checkpoint blockade. CMap analysis highlighted MS-275, a histone deacetylase (HDAC) inhibitor, as a promising compound targeting low SOCE_Score phenotypes. Conclusions: SOCE-related transcriptional features serve as robust biomarkers for prognosis and immune activity in neuroblastoma. The SOCE_Score holds potential for guiding risk stratification, immunotherapeutic selection, and drug repurposing efforts. These findings underscore the clinical utility of integrating calcium signaling profiles into neuroblastoma management and warrant further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.